Investigational Site Number: 3480002

Budapest H-1036

4 studies enrolling now · 12 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Rhinosinusitis With Nasal Polyps, Colitis Ulcerative, Crohn's Disease, Fabry Disease, Hemophilia, Hemophilia A, Hidradenitis Suppurativa, Plasma Cell Myeloma, Plasma Cell Myeloma Recurrent, Type 2 Diabetes Mellitus

Studies at this site

• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• Fabry Disease Registry & Pregnancy Sub-registry — Recruiting now
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Recruiting now
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Running, not enrolling
• A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps — Running, not enrolling
• Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis — Running, not enrolling
• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX — Running, not enrolling
• SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM — Running, not enrolling
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia — Stopped early
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed
• A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus — Completed